ANDERS WIKLUND/Getty Throughout the coronavirus pandemic, Sweden has drawn international attention for its unorthodox approach to managing the virus' spread. Unlike most European countries, Sweden didn't impose strict lockdown measures. Now it's reaping the rewards — economically speaking, at least. A report from Capital Economics published on Tuesday found that the Swedish economy was the…
Share on PinterestScientists have analyzed how Sweden’s minimal lockdown has impacted death rates. Sweden’s softer approach to lockdown involved closing universities and other schools for older pupils and recommending that anyone with COVID-19 symptoms and everyone over 70 self-isolate. Now, a new study suggests that these limited measures contributed to fewer deaths than expected. Still,…
Need help? Contact us We've detected unusual activity from your computer network To continue, please click the box below to let us know you're not a robot. Why did this happen? Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review…
Money or your life? — After limiting its lockdown, Sweden is neither success story nor disaster zone. John Timmer - Jun 6, 2020 12:00 pm UTC Enlarge / State epidemiologist Anders Tegnell of the Public Health Agency of Sweden has admitted that the pandemic response he promotes hasn't worked out as well as he hoped.…
Sweden is famously one of the few countries to have opted against a lockdown to contain the spread of the coronavirus. But given that the country has a much higher death toll per million than its Nordic neighbours, many observers have suggested that the Swedish approach has failed. While countries across the world have eased…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f